UK Says Illumina's $1B Genomic Sequencing Deal Problematic
The U.K.'s competition enforcer said Tuesday that DNA-sequencing company Illumina Inc.'s planned $1.2 billion purchase of Pacific Biosciences of California Inc. raises concerns about the supply of gene sequencing systems in...To view the full article, register now.
Already a subscriber? Click here to view full article